Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients
about
STEC-HUS, atypical HUS and TTP are all diseases of complement activation.Mannan-binding lectin in cardiovascular disease.Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarctionNew insights of an old defense system: structure, function, and clinical relevance of the complement system.Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injuryComplement factor B activation in patients with preeclampsia.Interactions between coagulation and complement--their role in inflammationMesenchymal stromal cells in renal ischemia/reperfusion injury.Mortality reduction in cardiac anesthesia and intensive care: results of the first International Consensus Conference.Complement in immune and inflammatory disorders: therapeutic interventions.Anti-inflammatory Agents: Present and FutureDelineating the relationships among the formation of reactive oxygen species, cell membrane instability and innate autoimmunity in intestinal reperfusion injury.Complement inhibition as a proposed neuroprotective strategy following cardiac arrestIs there a future for neuroprotective agents in cardiac surgery?Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy.The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.Ischemia/reperfusion injury: The role of immune cellsRole of complement and perspectives for intervention in ischemia-reperfusion damage.Targeting inflammation in cardiovascular diseases. still a neglected field?The innate immune response in reperfused myocardium.Preservation of myocardium during coronary artery bypass surgery.Myocardial protection in cardiac surgery: a historical review from the beginning to the current topics.Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS.Myocardial protection from ischemia-reperfusion injury post coronary revascularization.Complement anaphylatoxins C3a and C5a induce a failing regenerative program in cardiac resident cells. Evidence of a role for cardiac resident stem cells other than cardiomyocyte renewal.Pexelizumab and survival in cardiac surgery.Cardiopulmonary Bypass, Inflammation and How to Defy it: Focus on Pharmacological Interventions.Leucocyte expression of complement C5a receptors exacerbates infarct size after myocardial reperfusion injury.Rationale and design of the TETHYS trial: the effects of methotrexate therapy on myocardial infarction with ST-segment elevation.Circulatory assistance in acute heart failure--where do we go from here?Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition
P2860
Q33403359-08DDF220-B302-4771-A9B4-FB6DB47D555AQ33616097-BBC63FFC-E4F1-481A-B9BC-509F7C436D45Q34062698-71F1C584-EDB6-4A95-96E2-3F12204B2DAEQ34699496-CE23EFEE-7E8D-4E0A-B32C-8B57FD56FEACQ35246399-DED5C412-9534-498E-A1B3-A6432B9BC155Q35587280-3FA093DC-D7AC-4396-955D-2A7224E665EDQ36022738-EA1BC662-5CBB-4FDA-9A9C-A29C4E382EBEQ36070565-CA1B0063-124A-4EDD-8957-04436322F60AQ36358328-8950E6CE-4AF5-46F0-8B1B-3149B6F590F1Q36756854-7E852567-3051-4008-8F33-D728F61B2B4BQ37118156-F885DB0B-4535-40D1-8E90-5531E600B3D4Q37584355-583DFE15-7AFA-483D-AB9F-ADA1D419E3E8Q37691243-E36CD2FC-D32D-4DD5-8D42-97DD59226FD7Q37755882-C986D0B9-DBC4-4CD8-88EB-36A7A738A89DQ37774078-0900EF4F-8DC6-428C-8837-601631F6001CQ37808230-1AC8CF02-B86F-45B7-8C40-4D39D9DD65A4Q37821238-2521B6EB-AEB5-41C6-889F-8C071D5E6197Q37831329-FB3832E0-F1B2-4319-BB6A-E7ED12D7DDF7Q37925018-9F68C456-7E14-4723-8E48-4B13335A35E8Q37977824-FF91E649-69DC-4DDB-9BBB-43FA5F2E5B8CQ38005013-A68D2576-276D-4C92-BD05-DD76403DF1DAQ38123373-CB8E9295-3D9F-42F5-AD35-24F430BDE3D7Q38265002-3734A2AE-EBC7-41A8-9843-D09E2590B9FDQ38379218-CE1AD23B-91F6-4BAB-8642-F10E0A4D9AD4Q38552442-9286E9BD-7EBE-4BDB-AE34-FA821C54AE5AQ41379852-FDB04D5D-47AF-47B2-9DC4-AA7E7411A4F7Q41622583-8491B386-E651-46B1-9B05-A6C5544EF744Q41820543-6FF6DBCF-6576-44EC-9EA2-76CD9C5419CFQ47580544-17666E0B-6B90-454E-921B-932A2CCB94D8Q49069370-0934E612-5E5F-4C9B-815A-A3CD7C530C66Q50759737-EC317364-5788-4E37-97ED-9E9317F2DBA7Q57162899-64DE0379-5022-483D-8AA6-CF618AFA5E87
P2860
Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pexelizumab in ischemic heart ...... ta-analysis on 15,196 patients
@ast
Pexelizumab in ischemic heart ...... ta-analysis on 15,196 patients
@en
Pexelizumab in ischemic heart ...... ta-analysis on 15,196 patients
@nl
type
label
Pexelizumab in ischemic heart ...... ta-analysis on 15,196 patients
@ast
Pexelizumab in ischemic heart ...... ta-analysis on 15,196 patients
@en
Pexelizumab in ischemic heart ...... ta-analysis on 15,196 patients
@nl
prefLabel
Pexelizumab in ischemic heart ...... ta-analysis on 15,196 patients
@ast
Pexelizumab in ischemic heart ...... ta-analysis on 15,196 patients
@en
Pexelizumab in ischemic heart ...... ta-analysis on 15,196 patients
@nl
P2093
P31
P1476
Pexelizumab in ischemic heart ...... ta-analysis on 15,196 patients
@en
P2093
F Andreotti
P Agostoni
W J Van Gaal
P304
P356
10.1016/J.JTCVS.2007.12.062
P407
P577
2008-06-18T00:00:00Z